On the recordJune 27, 1996
I have a letter from Donna Shalala, the Secretary of HHS, and I quote from the letter that has been distributed throughout the Senate this afternoon. Secretary Shalala says: It will be nearly impossible to meet the substantial investment requirement under the Hatch substitute. She concludes saying: It would be virtually impossible for a manufacturer to obtain FDA approval for a generic drug product during this transition period.
Said by
William Pryor
Source
govinfo.gov